Logo image of ASXC

Asensus Surgical Inc (ASXC) Stock Fundamental Analysis

NYSEARCA:ASXC - NYSE Arca - US04367G1031 - Common Stock - Currency: USD

0.3479  +0 (+0.64%)

After market: 0.3487 +0 (+0.23%)

Fundamental Rating

2

Overall ASXC gets a fundamental rating of 2 out of 10. We evaluated ASXC against 189 industry peers in the Health Care Equipment & Supplies industry. While ASXC seems to be doing ok healthwise, there are quite some concerns on its profitability. ASXC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ASXC had negative earnings in the past year.
ASXC had a negative operating cash flow in the past year.
In the past 5 years ASXC always reported negative net income.
ASXC had a negative operating cash flow in each of the past 5 years.
ASXC Yearly Net Income VS EBIT VS OCF VS FCFASXC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -192.86%, ASXC is doing worse than 93.72% of the companies in the same industry.
With a Return On Equity value of -604.36%, ASXC is not doing good in the industry: 89.53% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -192.86%
ROE -604.36%
ROIC N/A
ROA(3y)-77.11%
ROA(5y)-102.82%
ROE(3y)-115.84%
ROE(5y)-144.56%
ROIC(3y)N/A
ROIC(5y)N/A
ASXC Yearly ROA, ROE, ROICASXC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

ASXC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASXC Yearly Profit, Operating, Gross MarginsASXC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

4

2. Health

2.1 Basic Checks

ASXC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ASXC has been increased compared to 1 year ago.
The number of shares outstanding for ASXC has been increased compared to 5 years ago.
ASXC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ASXC Yearly Shares OutstandingASXC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
ASXC Yearly Total Debt VS Total AssetsASXC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -37.31, we must say that ASXC is in the distress zone and has some risk of bankruptcy.
ASXC has a worse Altman-Z score (-37.31) than 93.19% of its industry peers.
ASXC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.31
ROIC/WACCN/A
WACC8.7%
ASXC Yearly LT Debt VS Equity VS FCFASXC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

ASXC has a Current Ratio of 1.00. This is a bad value and indicates that ASXC is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.00, ASXC is doing worse than 92.67% of the companies in the same industry.
A Quick Ratio of 0.69 indicates that ASXC may have some problems paying its short term obligations.
ASXC has a worse Quick ratio (0.69) than 92.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1
Quick Ratio 0.69
ASXC Yearly Current Assets VS Current LiabilitesASXC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

ASXC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.65%, which is quite good.
The Revenue has grown by 20.97% in the past year. This is a very strong growth!
ASXC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.67% yearly.
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)20.97%
Revenue growth 3Y39.2%
Revenue growth 5Y-18.67%
Sales Q2Q%104.44%

3.2 Future

The Earnings Per Share is expected to grow by 19.08% on average over the next years. This is quite good.
Based on estimates for the next years, ASXC will show a very strong growth in Revenue. The Revenue will grow by 79.22% on average per year.
EPS Next Y21.03%
EPS Next 2Y17.25%
EPS Next 3Y20.2%
EPS Next 5Y19.08%
Revenue Next Year43.58%
Revenue Next 2Y61.51%
Revenue Next 3Y82.88%
Revenue Next 5Y79.22%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ASXC Yearly Revenue VS EstimatesASXC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ASXC Yearly EPS VS EstimatesASXC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ASXC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASXC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASXC Price Earnings VS Forward Price EarningsASXC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASXC Per share dataASXC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

ASXC's earnings are expected to grow with 20.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.25%
EPS Next 3Y20.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASXC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Asensus Surgical Inc

NYSEARCA:ASXC (8/21/2024, 8:05:47 PM)

After market: 0.3487 +0 (+0.23%)

0.3479

+0 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2024-08-13/amc
Earnings (Next)11-12 2024-11-12/amc
Inst Owners0.02%
Inst Owner Change0%
Ins Owners0.13%
Ins Owner Change0%
Market Cap94.62M
Analysts45.71
Price Target0.36 (3.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.2%
Min EPS beat(2)-56.86%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)-9.68%
Min EPS beat(4)-56.86%
Max EPS beat(4)26.47%
EPS beat(8)4
Avg EPS beat(8)-7.14%
EPS beat(12)8
Avg EPS beat(12)-2.75%
EPS beat(16)12
Avg EPS beat(16)6.09%
Revenue beat(2)1
Avg Revenue beat(2)-3.78%
Min Revenue beat(2)-8.03%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-13.71%
Min Revenue beat(4)-46.28%
Max Revenue beat(4)0.46%
Revenue beat(8)1
Avg Revenue beat(8)-18.28%
Revenue beat(12)3
Avg Revenue beat(12)1.25%
Revenue beat(16)7
Avg Revenue beat(16)7.58%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)-29.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.87
P/FCF N/A
P/OCF N/A
P/B 7.28
P/tB 7.96
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.03
BVpS0.05
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -192.86%
ROE -604.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.11%
ROA(5y)-102.82%
ROE(3y)-115.84%
ROE(5y)-144.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.31%
Cap/Sales 5.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1
Quick Ratio 0.69
Altman-Z -37.31
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)12.1%
Cap/Depr(5y)7.97%
Cap/Sales(3y)13.75%
Cap/Sales(5y)9.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y21.03%
EPS Next 2Y17.25%
EPS Next 3Y20.2%
EPS Next 5Y19.08%
Revenue 1Y (TTM)20.97%
Revenue growth 3Y39.2%
Revenue growth 5Y-18.67%
Sales Q2Q%104.44%
Revenue Next Year43.58%
Revenue Next 2Y61.51%
Revenue Next 3Y82.88%
Revenue Next 5Y79.22%
EBIT growth 1Y-4.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.25%
OCF growth 3YN/A
OCF growth 5YN/A